InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,699.71
(
-0.24%
)
US TECH 100
19,271.20
(
-0.33%
)
Dow Jones
42,028.24
(
0.01%
)
Brent Oil
74.13
(
-0.26%
)
Bitcoin
62,944.50
(
-0.01%
)
Post# of 20775
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

da_wiz_waz_ere

Send PM Follow Ignore
Followers 0
Posts 14
Boards Moderated 0
Alias Born 04/17/2014

da_wiz_waz_ere

Re: Gary A 1 post# 13830

Friday, 04/18/2014 1:46:27 PM

Friday, April 18, 2014 1:46:27 PM

Post# of 20775
Intellect Neurosciences holds worldwide development and commercialization rights to TauC3 under an exclusive license agreement with Northwestern University. Also, Intellect owns pending patent applications relating to antibodies targeting fragments of Tau in the brain for treatment of Alzheimer’s and other tauopathies (e.g. Chain, 2011: Treatment of Tauopathies, WO 2012/106363 published November 15, 2012).

A January 2014 quote from Mr. Elliot Maza.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up